“`html
Randomized Placebo-Controlled Clinical Trial of Dutasteride for Reducing Heavy Drinking in Men
ABSTRACT
Prior studies have shown that dutasteride, commonly used for benign prostatic hypertrophy, can reduce the production of certain neuroactive steroids associated with alcohol’s effects. This study aimed to evaluate the effectiveness and safety of dutasteride in reducing heavy drinking in men.
METHODS
142 men with heavy drinking habits were randomly assigned to receive either a placebo or 1 mg of dutasteride daily for 12 weeks, with the goal of abstaining from alcohol or reducing intake to nonhazardous levels. The hypothesis was that dutasteride would lead to a greater reduction in drinking.
RESULTS
Analysis showed that dutasteride treatment led to a significant reduction in drinking compared to the placebo. By the end of the 12-week treatment, 25% of those on dutasteride had no hazardous drinking, compared to 6% on placebo. The drug was well tolerated, with stomach discomfort and reduced libido being the most common adverse events reported in the dutasteride group.
CONCLUSION
Overall, dutasteride at a daily dose of 1 mg was effective in reducing heavy drinking in men seeking treatment. It was particularly beneficial for those with elevated drinking to cope motives.
Clinical trials like this are instrumental in developing safe and effective treatments, and it’s important to implement their findings into everyday medical practice. Our AI-driven platform, DocSym, consolidates clinical standards and research, while our mobile apps streamline patient care and digital services, ultimately improving outcomes and reducing administrative burden.
AI-powered solutions have the potential to enhance clinic workflows and patient outcomes, as well as minimize paper-based routines. Learn more about how we can help at aidevmd.com.
“`
